Login to Your Account



DBV extending allergy patch technology into vaccine development

By Cormac Sheridan
Staff Writer

Tuesday, September 6, 2016

DUBLIN – DBV Technologies SA is extending its patch-based antigen delivery technology, which is currently undergoing a pivotal phase III trial in a food allergy indication, into its first vaccine study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription